Liminal BioSciences Inc. (LMNL)
Company Description
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom.
The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases.
It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage.
The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Health Care |
| Employees | 251 |
| CEO | Kenneth Galbraith |
Contact Details
Address:
440 Boulevard Armand Laval, Quebec H7V 4B4 Canada | |
| Phone | 450 781 0115 |
| Website | liminalbiosciences.com |
Stock Details
| Ticker Symbol | LMNL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| CIK Code | 1351172 |
| CUSIP Number | 53272L103 |
| ISIN Number | CA53272L1031 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Bruce Pritchard BA, CA, FIOD | Chief Executive Officer |
| Patrick Sartore | President |
| Marie Iskra | Corporate Secretary and General Counsel |
| N. Nicole Rusaw C.A., CPA | Interim Chief Financial Officer |
| Shrinal Inamdar | Manager of Investor Relations and Communications |
| Dr. Steven J. Burton | President of Prometic Bioseparations Ltd |
| Dr. John Bienenstock CM, FRCP, FRPC, FRSC, M.D.(Hon) | Member of Advisory Committee - Therapeutics |
| Dr. Christopher L. Penney | Chief Scientific Officer of Therapeutics - ProMetic BioSciences Inc |
| Dr. Robert G. Rohwer | Member of Scientific Advisory Committee - PRDT |
| Dr. Volker Helrich | Member of Scientific Advisory Committee - Therapeutics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 21, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| Jun 6, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| May 24, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| May 23, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| May 10, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| May 9, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| May 9, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| May 3, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| Apr 1, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| Mar 17, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |